News

Pfizer Inc. announced the European Commission (EC) has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor (HER2)…
Read More...

Shionogi & Co., Ltd. announced that, after completing a Priority Review, the U.S. Food and Drug Administration (FDA) has approved Mulpleta (lusutrombopag), a once-daily, orally…
Read More...

Abdi Ibrahim has carefully selected rfxcel to implement and support new compliance management and serialisation processing software to ensure full compliance with current and future…
Read More...

Torque, an immuno-oncology company developing first-in-class Deep Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today a…
Read More...

Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced that, based on achievement of technical milestones, it has…
Read More...

Nutriband Inc announced the formal completion of the acquisition of Atlanta-based 4P Therapeutics Inc. Pursuant to the previously announced acquisition agreement, on Aug 1, 2018,…
Read More...

Puma Biotechnology announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for the medicinal product NERLYNX (neratinib) for the extended adjuvant…
Read More...

LEO Pharma and Bayer announced that LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit. The portfolio to be acquired includes branded…
Read More...

Takeda Pharmaceutical Company Limited and TiGenix NV announced that Takeda has acquired all outstanding ordinary shares (including Ordinary Shares represented by American Depositary…
Read More...

IBSA Group, the largest privately owned pharmaceutical company in Switzerland, has established a commercial presence in the United States as IBSA Pharma Inc. and is planning to directly…
Read More...

HiFiBiO Therapeutics announced a multi-target agreement with Takeda Pharmaceutical Company Limited (Takeda) to enable the discovery of breakthrough antibody therapies to potentially…
Read More...

Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment…
Read More...

CStone Pharmaceuticals (CStone) announced that its IND application for CS3006, a small-molecule inhibitor of mitogen-activated protein kinase (MEK), has been approved by the China…
Read More...

Eli Lilly and Company announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have…
Read More...

AstraZeneca and MedImmune, its global biologics research and development arm, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Read More...

MilliporeSigma and InnoCore Pharmaceuticals; Groningen, Netherlands, have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys biodegradable polymer…
Read More...

Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved PERSERISTM, the first once-monthly subcutaneous risperidone-containing,…
Read More...

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial…
Read More...

Genprex has entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center under which Genprex will sponsor a pre-clinical study, entitled “A Novel…
Read More...

Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the…
Read More...